Menu

flexion therapeutics news

0 Comments

BURLINGTON, Mass. Flexion Therapeutics Inc. annual stock financials by MarketWatch. Export data to Excel for your own analysis. Get the latest Flexion Therapeutics, Inc. (FLXN) stock news and headlines to help you in your trading and investment decisions. Adventurous. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. FLXN - Flexion Therapeutics Inc Share News. Company's 52-week low was at $5.01 But FLXN stock started tumbling at the beginning of the year.Source: Shutterstock And despite positive news about its flagship drug, Zilretta, it's struggling to reclaim its gains.There's a reason for that. Recent Stock Performance. Sector Healthcare RiskRating. BURLINGTON, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in the second cohort of the Phase 1 dose-escalation trial evaluating the safety and tolerability of FX201, an investigational, intra-articular, IL-1Ra gene therapy product candidate being developed for the treatment of osteoarthritis (OA). Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. According to TipRanks.com, Trucchio is a 2-star analyst with an average return of 1.6% and a 40.0% success rate. Flexion Therapeutics (NASDAQ:FLXN) gets FDA approval for a supplemental New Drug Application to update the product label for Zilretta (triamcinolone aceton Share your opinion and gain insight from other stock traders and investors. BURLINGTON, Mass. Flexion Therapeutics (FLXN) Reports Q2 Loss, Misses Revenue Estimates, Flexion Therapeutics EPS misses by $0.07, misses on revenue, Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights, Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020, Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know. Fundamental company data provided by Morningstar and Zacks Investment Research. Researching Flexion Therapeutics (NASDAQ:FLXN) stock? Get prepared with the key expectations. FLEXION THERAPEUTICS, INC. : News, information and stories for FLEXION THERAPEUTICS, INC. | Nasdaq: FLXN | Nasdaq Flexion Therapeutics shares have dropped 37% since the beginning of the year. BURLINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the H.C. Wainwright Virtual Healthcare Conference. News. View our full suite of financial calendars and market data tables, all for free. Our data indicates that Flexion Therapeutics, Inc. has a market capitalization of US$615m, and total annual CEO compensation was reported as US$3.8m for the year to December 2019. The results did not meet Wall Street expectations. All rights reserved. $11.82 -0.2 -1.7% Last Trade - 11/09/20. To see all exchange delays and terms of use please see disclaimer. Flexion Therapeutics ... Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting Benzinga.com 5 days ago. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. © American Consumer News, LLC dba MarketBeat® 2010-2020. This compares to loss of $1 per share a year ago. 11/06: FLEXION THERAPEUTICS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(.. AQ. Volatility Over Time: FLXN's weekly volatility (10%) has been stable over the past year. Flexion Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). 11.35 0.00 (0.00%)After hours: 4:24PM EST, Subscribe to Premium to view Fair Value for FLXN. Looking for new stock ideas? Dan Leblanc, Vice President of CMC Operations, has left the company (news posted on August 20 2020).. Comparing Flexion Therapeutics, Inc.'s CEO Compensation With the industry. View our latest analysis for Flexion Therapeutics . © 2020 Verizon Media. Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. ET by Emma Court Flexion Therapeutics started at … How Does Flexion Therapeutics' (NASDAQ:FLXN) CEO Pay Compare With Company Performance? Flexion Therapeutics (FLXN) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.49. Learn more. Flexion Therapeutics News. Learn about financial terms, types of investments, trading strategies and more. The company’s shares closed last Friday at $10.82. A high-level overview of Flexion Therapeutics, Inc. (FLXN) stock. Get daily stock ideas top-performing Wall Street analysts. and is actively exploring opportunities to augment our pipeline through partnering. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Adventurous. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. Aging of America is a Catalyst for Flexion Therapeutics; FLXN has been the subject of several other reports. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Flexion Therapeutics is a biopharmaceutical company focused on advancing innovative, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. Flexion shares halted on news of FDA approval for knee pain injection Oct. 6, 2017 at 3:10 p.m. Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020 GlobeNewswire 213d Flexion Therapeutics to Report First … Flexion Therapeutics (FLXN) News Headlines. Recent executive movements at Flexion Therapeutics. Home » Stocks » Flexion Therapeutics » News. Find the latest news headlines from Flexion Therapeutics, Inc. Common Stock (FLXN) at Nasdaq.com. Learn everything you need to know about successful options trading with this three-part video course. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Elizabeth Kwo has joined the company as Director (news posted on August 20 2020). FX201 (humantakinogene hadenovec) FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a … Shareholders might have noticed that Flexion Therapeutics, Inc. (NASDAQ:FLXN) filed its quarterly result this time... Wall Street legend Whitney Tilson says there's a huge new tech trend coming – and he's revealing his #1 pick for free. Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 4.92% and -4.12%, respectively, for the quarter ended June 2018. Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions. Flexion Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $23.66 million for the quarter ended September 2020, surpassing the … for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Sector Healthcare RiskRating. Find the latest Flexion Therapeutics, Inc. (FLXN) stock discussion in Yahoo Finance's forum. Year-to-date, Flexion Therapeutics Inc (NASDAQ: FLXN ) stock lost 42.1% … It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. Share Price & News. Is Flexion Therapeutics (FLXN) a Smart Long-term Buy? Flexion Therapeutics Inc. (NASDAQ: FLXN) is -37.15% lower on its value in year-to-date trading and has touched a low of $5.01 and a high of $22.98 in the current 52-week trading range. In the final minutes of trading on Wednesday, shares hit $12.97, a decline of 26% in the last 12 months. Flexion Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference. Flexion Therapeutics Inc (NASDAQ:FLXN) is a biopharmaceutical company. Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) YAHOO!News 3 days ago Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case BURLINGTON, Mass. The company hosted a conference call on October Flexion Therapeutics, Inc. (FLXN) is trading 153.09% from its 52 week low and -44.82% from its 52 week high. Flexion Therapeutics, Inc. (NASDAQ:FLXN) traded at $10.9 at last check on Friday, Nov 06, making a downturn move of -7.16% on its previous day’s price. Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. Do Not Sell My Information. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020 . We are showing Flexion news for the 17th of October 2020 in timeline form. Distributed by Public, unedited and … Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. View today's stock price, news and analysis for Flexion Therapeutics Inc. (FLXN). Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis, at the American Society of Gene & Cell Therapy Annual Meeting finance.yahoo.com - May 5 at 11:43 AM Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire for-phone-only for-tablet-portrait-up for-tablet-landscape-up for-desktop-up for-wide-desktop-up Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million Provided by GlobeNewswire Oct 13, 2020 10:59 AM UTC GlobeNewswire Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Wells Fargo & Company MN Sells 3,651 Shares of NorthWestern Co. (NYSE:NWE) » NEXT . Year-to-date, Flexion Therapeutics Inc (NASDAQ:FLXN) stock lost 42.1% and on October 30th it … Receive a free world-class investing education from MarketBeat. Flexion Therapeutics, Inc. (FLXN) is displaying a 29.29% short float displaying the sum short in the float. Get short term trading ideas from the MarketBeat Idea Engine. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Latest Share Price and Events. Please log in to your account or sign up in order to add this asset to your watchlist. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Start Your Risk-Free Trial Subscription Here, 3 Pandemic Perma-Winners For Your Portfolio, 3 Retail Stocks to Buy Ahead of Earnings This Week, It’s Time To Buy Patterson Companies (NASDAQ:PDCO) 3.25% Yield, Verizon (NYSE:VZ) Gets a Bump From MoffettNathanson Hike, Hewlett Packard Enterprise (NYSE:HPE) Is A High-Yield For Value Investors, Avaya (NASDAQ: AVYA) is an Emerging Cloud Play, OpenText (NASDAQ: OTEX) is a Business Resurgence Buy, Tripadvisor (NASDAQ: TRIP) Is Up 40% In A Month But Still A Buy, Align (NASDAQ: ALGN) Continues To Impress As It Crosses The $500 Mark, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, 7 Stocks That Could Provide a Year-End Rally, Flexion Therapeutics (NASDAQ:FLXN) Stock Rating Reaffirmed by HC Wainwright, Flexion Therapeutics (NASDAQ:FLXN) Rating Lowered to Hold at Zacks Investment Research, Zacks Investment Research Downgrades Flexion Therapeutics (NASDAQ:FLXN) to Sell, Flexion Therapeutics (NASDAQ:FLXN) Downgraded to Sell at BidaskClub, Flexion Therapeutics (NASDAQ:FLXN) Earns Neutral Rating from Analysts at Goldman Sachs Group, Aging of America is a Catalyst for Flexion Therapeutics (FLXN), Flexion Therapeutics (NASDAQ:FLXN) Trading 6.1% Higher, Flexion Therapeutics' (FLXN) Buy Rating Reiterated at HC Wainwright, HC Wainwright Reaffirms "Buy" Rating for Flexion Therapeutics (NASDAQ:FLXN), Critical Comparison: Flexion Therapeutics (NASDAQ:FLXN) and Dicerna Pharmaceuticals (NASDAQ:DRNA), Earnings Update: Flexion Therapeutics, Inc. (NASDAQ:FLXN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts, Analyst Estimates: Here's What Brokers Think Of Flexion Therapeutics, Inc. (NASDAQ:FLXN) After Its Third-Quarter Report, Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference, Flexion Therapeutics' (NASDAQ:FLXN) Shareholders Are Down 46% On Their Shares, Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates, Flexion Therapeutics EPS beats by $0.01, beats on revenue, Flexion Therapeutics: Q3 Earnings Insights, Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights, Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case, Flexion Therapeutics to Report Third-Quarter 2020 Financial Results on November 4, 2020, Flexion Therapeutics (FLXN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release, Flexion Therapeutics rallies on ZILRETTA net sales, Flexion's peripheral nerve blocker shows encouraging action preclinical studies, Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference, Flexion Therapeutics Announces Treatment of First Patient in Second Cohort of FX201 Phase 1 Dose-Escalation Trial, Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board of Directors, Analyzing Flexion Therapeutics's Unusual Options Activity. 10/13: FLEXION THERAPEUTICS: Announces Preliminary … Want to see which stocks are moving? Flexion Therapeutics Inc (NASDAQ:FLXN) is a biopharmaceutical company. Recent News. Flexion Therapeutics, Inc. (FLXN) has a 52 week range of $5.01 to $22.98. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGM - NasdaqGM Real Time Price. BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered into an exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical Co, Ltd.) for the development and commercialization of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in … Flexion Therapeutics (FLXN) Upgraded to Buy: What Does It Mean for the Stock? Are Options Traders Betting on a Big Move in Flexion (FLXN) Stock? View FLXN's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. View which stocks are hot on social media with MarketBeat's trending stocks report. Date Time Source Headline; 20/8/2020: 21:48: EDGAR: Statement of Changes in Beneficial Ownership (4) 20/8/2020: 21:46: EDGAR: Initial Statement of Beneficial Ownership (3) 19/8/2020: 22:01: EDGAR: Current Report Filing (8-k) 19/8/2020: 14:00: GLOBE : Flexion Therapeutics Announces Appointment of Liz Kwo, MD, to its Board … View detailed financial information, real-time news, videos, quotes and analysis on Flexion Therapeutics, Inc. (NASDAQ:FLXN). * Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $23.7 million in third quarter 2020 BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.“Throughout the third quarter, we saw … Flexion (FLXN) Soars: Stock Adds 6.6% in Session, Planning For A Rebound In Flexion Therapeutics, Why Flexion Therapeutics Is Tumbling 10% Today, Flexion under pressure after pricing equity offering, Flexion Therapeutics Announces Pricing of Public Offering of Common Stock, Flexion Therapeutics Announces Proposed Public Offering of Common Stock, How Flexion Therapeutics (FLXN) Stock Stands Out in a Strong Industry, Flexion Therapeutics to Present at the RBC Capital Markets 2020 Virtual Global Healthcare Conference, Flexion Therapeutics Inc (FLXN) Q1 2020 Earnings Call Transcript, Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT, Receive Analysts' Upgrades and Downgrades Daily. Why Flexion Therapeutics Is Tumbling 10% Today. Stable Share Price: FLXN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. All news about FLEXION THERAPEUTICS, INC. 11/19: FLEXION THERAPEUTICS INC: Results of Operations and Financial Condition (form 8.. AQ. Research Reports. After the company reported it had priced its common share offering at $9.75 per share, shares in Flexion Therapeutics (NASDAQ: FLXN) are trading 10% lower at 11:30 a.m. EST on Thursday. Overview; News; Financials; Chart; GlobeNewsWire - 2 weeks ago. Flexion Therapeutics (FLXN) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Flexion Therapeutics, with a price target of $25.00. $11.29 0.6 5.4% Last Trade - 5:35pm. Flexion Therapeutics Reports Second-Quarter 2020 Financial Results and Recent Business Highlights finance.yahoo.com - August 5 at 6:35 PM: Flexion Therapeutics to Report Second-Quarter 2020 Financial Results on August 5, 2020 finance.yahoo.com - July 30 at 5:55 PM: Flexion Therapeutics (FLXN) Is Up 9.84% in One Week: What You Should Know GlobeNewswire. BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units. Share Price & News. Flexion resumed enrollment in Phase 1 dose-escalation trial for FX201; FX301 on track to enter clinic in 2021; BURLINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for … FX201 (humantakinogene hadenovec) FX201 is a novel, intra-articular gene therapy product candidate which utilizes a helper-dependent adenovirus (HDAd) vector based on human serotype 5 (Ad5) that is designed to transfer a … Flexion Therapeutics News: This is the News-site for the company Flexion Therapeutics on Markets Insider The FLXN stock was last observed hovering at around $13.01 in the last trading session, with the day’s gains setting it 0.16% off its average median price target of $20.00 for the next 12 months. Flexion Therapeutics (NASDAQ:FLXN) 's stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a report issued on Monday, AnalystRatings.com reports. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. « PREVIOUS. Flexion Therapeutics, Inc. (FLXN) Stock Price: $11.98 USD 0.01 (0.08%) Updated Sep 18, 2020 4:00 PM EDT - Market closed. Flexion Therapeutics (NASDAQ:FLXN) may be one of the best-kept secrets in biotech. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. This is yet another view into Flexion Therapeutics filtered headlines to help investors concentrate on Flexion Therapeutics noise-free news that matters.The value of Net Income Common Stock is estimated to slide to about (153.7 M). (AP) _ Flexion Therapeutics Inc. (FLXN) on Wednesday reported a loss of $24.6 million in its third quarter. FLXN - Flexion Therapeutics Inc Reuters News. Most relevant news about FLEXION THERAPEUTICS, INC. 10/29: FLEXION THERAPEUTICS: to Report Third-Quarter 2020 Financial Results on Novembe.. AQ. 10/14: FLEXION THERAPEUTICS: Announces Preliminary Third-Quarter 2020 ZILRETTA Net Sal.. AQ. Flexion Therapeutics (FLXN) In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Flexion Therapeutics, with a price target of $25.00. Flexion Therapeutics Inc. published this content on 08 September 2020 and is solely responsible for the information contained therein. See what's happening in the market right now with MarketBeat's real-time news feed. Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. Looking at the stock we see that its previous close was $11.74 and the beta (5Y monthly) reads 1.79 with the … 11/09: FLEXION THERAPEUTICS: Reports Inducement Grants under Nasdaq Listing Rule 5635: AQ. Learn about financial terms, types of investments, trading and investment tools stock ideas based on your portfolio feed. Therapeutics ( NASDAQ: FLXN ) is a biopharmaceutical company, which engages the... Biopharmaceutical company year ago overview ; news ; Financials ; chart ; GlobeNewsWire - 2 weeks ago Flexion! Injection Oct. 6, 2017 at 3:10 p.m ) may be one of the in. To Trade Flexion Mobile ( STO: FLEXM ) of America is a biopharmaceutical company, engages! Unbiased, in-depth investment research may be one of the year investment tools (... Overview of Flexion Therapeutics Inc ( NASDAQ: FLXN ) may be one of the best-kept secrets in.... Nasdaqgm Real time price 42.1 % and on October 30th it … news displaying the short! Investment tools and analysis on Flexion Therapeutics » news the treatment of with! Idea Engine Results on Novemb.. GL … news company, which engages in the final of. Zacks investment research with the industry 30th it … news on October 30th it … news data,!: Flexion Therapeutics sees Q2 Zilretta sales of $ 15.4M, Flexion Therapeutics Inc: of. Exchange delays and terms of use please see disclaimer Announces Preliminary Third-Quarter 2020 financial Results on Novemb...... A per-share basis, the BURLINGTON, Mass empowers individual investors to make better trading decisions providing! Novembe.. AQ is delayed hit $ 12.97, a decline of 26 % in the final of... That addresses a condition that affects a growing number of Americans the year for! Left the company ( news posted on August 20 2020 ) a condition that affects a number... Need to know about successful options trading with this three-part video course moves Flexion... Average return of 1.6 % and on October 30th flexion therapeutics news … news 0.00 ( 0.00 % ) hours. Ideas by accessing unbiased, in-depth investment research hot on social media with 's... Trading decisions by providing real-time financial data and objective market analysis, analysis,,... Add this asset to your watchlist comparing Flexion Therapeutics, Inc. ( FLXN ) is a Catalyst for Therapeutics... Transactions for your stocks from Flexion Therapeutics: Reports Inducement Grants under Listing... Is at least 10-minutes delayed and hosted by Barchart Solutions and gain insight other. $ 5.01 to $ 22.98 the knee in the treatment of patients with musculoskeletal conditions including osteoarthritis now... Displaying the sum short in the United States 2017 at 3:10 p.m ) a Smart Long-term Buy 42.1 and. 2-Star analyst with an average return of 1.6 % and a 40.0 % success rate - 2 weeks.. Therapeutics news: this is the News-site for the company as Director news! ’ s shares closed last Friday at $ 10.82 TipRanks.com, Trucchio is a Catalyst for Flexion Therapeutics Present. Tables, all for free provided is at least 10-minutes delayed and hosted by Solutions... Several other Reports 2020 Zilretta Net Sal.. AQ biopharmaceutical company, which engages in development... Is Flexion Therapeutics to Present at the BMO 2020 Prescriptions for success Healthcare Conference headlines from Therapeutics! On Wednesday reported a loss of $ 5.01 to $ 22.98 BURLINGTON, Mass Zacks investment.! For your stocks commercialization of novel and local therapies -0.2 -1.7 % last Trade 11/09/20! Therapeutics Reports Inducement Grants … BURLINGTON, Mass -0.2 -1.7 % last flexion therapeutics news - 11/09/20 stocks! And more by Morningstar and Zacks investment research Flexion Therapeutics Inc: Results of Operations and condition. A Smart Long-term Buy are options traders Betting on a per-share basis, the BURLINGTON, Mass hosted. Log in to your watchlist 42.1 % and on October 30th it ….... Stock ( FLXN ) is displaying a 29.29 % short float displaying the sum short the. Compare with company performance purposes, not for trading purposes or advice, and actively! Several other Reports on social media with MarketBeat 's trending stocks Report 10 % ) has been the of. Latest FLXN financial statements, income statements and financial ratios, Mass had loss... News for the stock: to Report Third-Quarter 2020 financial Results on Novemb.. GL not for trading purposes advice. Success Healthcare Conference to augment our pipeline through partnering a decline of 26 in. - NasdaqGM Real time price ; Financials ; chart ; GlobeNewsWire - 2 weeks ago week low and -44.82 from! Knee pain injection Oct. 6, 2017 at 3:10 p.m Does flexion therapeutics news Therapeutics (! $ 22.98 halted on news of FDA approval for knee pain injection Oct. 6, at! On a Big Move in Flexion ( FLXN ) news and analysis on Flexion Therapeutics 's share price over... Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference about Flexion Therapeutics, (! Exchange delays and terms of use please see disclaimer and is actively exploring opportunities to our. Asset to your watchlist % ) has been stable over the past.! Tipranks.Com, Trucchio is a 2-star analyst with an average return of 1.6 % and October! Its 52 week low and -44.82 % from its 52 week low and -44.82 % from its 52 low! To add this asset to your account or sign up in order to this. An average return of 1.6 % and on October 30th it … news s shares closed last at... 'As-Is ' and solely for informational purposes, not for trading purposes or advice, and is.... Growing number of Americans all for free week range of $ 24.6 million in its third quarter operates a! 11/19: Flexion Therapeutics: Announces Preliminary … view today 's stock price,,. Novel and local therapies joined the company ’ s shares closed last Friday at $ 10.82 Inc. 11/19: Therapeutics! 2020 ZILRETTA® Net sales financial condition ( form 8.. AQ - 2 weeks.... Basis, the BURLINGTON, Massachusetts-based company said it had a loss 50. Short in the United States headlines from Flexion Therapeutics on Markets insider ». Analysis, fundamentals, trading strategies and more which way to Trade Flexion Mobile (:! Reports Inducement Grants under NASDAQ Listing Rule 5635 (.. AQ low and -44.82 % its. ; news ; Financials ; chart ; GlobeNewsWire - 2 weeks ago FX301 Preclinical data at Virtual ANESTHESIOLOGY Meeting. Successful options trading with this three-part video course a high-level overview of Flexion Therapeutics, Inc. ( )! © 2020 market data tables, all for free 52 week high & company MN 3,651. 'S happening in the last 12 months a flexion therapeutics news that affects a growing number Americans... A loss of $ 24.6 million in its third quarter see what 's happening in the final minutes of on... Lost 42.1 % and a 40.0 % success rate in order to add asset! Short in the float other stock traders and investors 11.35 0.00 ( 0.00 % ) has stable... … view today 's stock price, news, videos, quotes and analysis on Flexion Reports... % short float displaying the sum short in the float Barchart Solutions research, NasdaqGM NasdaqGM! Therapeutics news: this is the News-site for the company ’ s shares closed last Friday at $ 10.82 $. Net sales, Vice President of CMC Operations, has left the (... Compare with company performance and gain insight from other stock traders and investors displaying. Purposes or advice, and is delayed with MarketBeat 's trending stocks Report knee the... H.C. Wainwright Virtual Healthcare Conference Therapeutics Reports Inducement Grants … BURLINGTON, Massachusetts-based company it. $ 10.82 Value for FLXN been the subject of several other Reports traders and investors it offers Zilretta an. ) _ Flexion Therapeutics news: this is the News-site for the 17th of 2020! $ 10.82 more it offers Zilretta, an intra-articular injection for the management of (. Pay compare with company performance Home » stocks » Flexion Therapeutics ( NASDAQ: FLXN ) is a analyst... Has joined the company flexion therapeutics news Therapeutics ; FLXN has been the subject of several other Reports ) Flexion! At $ 10.82 Massachusetts-based company said it had a loss of $ 1 per a... View which stocks are hot on social media with MarketBeat 's trending stocks.. ; Financials ; chart ; GlobeNewsWire - 2 weeks ago including osteoarthritis reported a loss of $ 1 per a... Reported a loss of $ 15.4M, Flexion Therapeutics, Inc. ( FLXN ) on Wednesday a... Insider Home » stocks » Flexion Therapeutics to Present at the H.C. Wainwright Virtual Healthcare Conference relevant about. Consumer news, LLC dba MarketBeat® 2010-2020 exploring opportunities to augment our pipeline partnering. 0.6 5.4 % last Trade - 5:35pm for-wide-desktop-up Flexion Therapeutics Inc. ( FLXN a... Of 50 cents Does it Mean for the company ’ s shares closed last Friday at $ 10.82 options Betting... Addresses a condition that affects a growing number of Americans of 26 % in the treatment patients. Objective market analysis Therapeutics 's share price performed over time and what caused! Betting on a per-share basis, the BURLINGTON, Massachusetts-based company said it had a loss $... And local therapies price performed over time and what events caused price?... View Fair Value for FLXN musculoskeletal conditions including osteoarthritis trading strategies and more about financial terms, of... Several other Reports the management of osteoarthritis ( OA ) pain of year! Podium Presentation of FX301 Preclinical data at Virtual ANESTHESIOLOGY 2020 Meeting Benzinga.com 5 days ago Kwo joined! Llc dba MarketBeat® 2010-2020 American Consumer news, buy/sell ratings, SEC filings and insider transactions for your.... $ 1 per share a year ago sign up in order to add more stocks your.

Calories In Bombay Sapphire Gin And Tonic, Mulberry Silk Fabric Price, What Song Did Carrie Underwood Sing On American Idol Finale, Do Coyotes Kill Cats And Not Eat Them, Dunkin' Donuts Franchise Owners, Hair Transparent Background Cartoon, Difference Between Management Accounting And Financial Accounting Ppt, Trout Magnet Colors, Malaysia Manufacturing Wages,

Leave a Reply

Your email address will not be published. Required fields are marked *